AI is firing these small caps this morning

AI is firing these small caps this morning

[adrotate group="2"]

& The Motley Fool

Hello, 360!

Here are some of our top movers for the day. For more trade ideas, simply text โ€œRAGEโ€ to 1-(888) 404-5747 (remember to include the โ€œ1โ€!). Yesterdayโ€™s alert saw a closing rise of over 15% in spite of market turbulence. Stay excited and informed!


FOCUS LIST๐Ÿ”Ž

SANA โ€“ Surged over 240% in pre-market after reporting promising clinical results in Type 1 Diabetes islet cell transplantation without the need for immunosuppression.

CURR โ€“ Gained over 180% in pre-market following the launch of SEAMLESS AI call center solutions.

ABSI โ€“ Increased by over 50% in pre-market after revealing a collaboration and strategic investment with AMD aimed at enhancing AI drug discovery.


*Sponsored by The Motley Fool

Fortune Favors The Bold

Unnamed Image

Ever wished you could rewind time and invest in Amazon during its early days? Get ready, as the AI revolution presents a second chance.

In The Motley Foolโ€™s latest report, explore the realm of AI innovation. Discover why experts refer to it as โ€œthe rocket fuel of AI,โ€ predicting a market cap 41 times greater than Amazonโ€™s.

Donโ€™t let former regrets restrain you. Seize your future and harness the AI wave with The Motley Foolโ€™s exclusive report.

Whether itโ€™s AI or Amazon, remember: fortune favors the bold.

Donโ€™t miss out; check out the report today.


HOTLIST๐Ÿ”ฅ

SANA โ€“ Surged over 240% in pre-market after releasing positive clinical results regarding type 1 diabetes islet cell transplantation without immunosuppression.

Sana Biotechnology Inc. (SANA) is dedicated to utilizing engineered cells as therapeutic solutions.

In after-hours trading yesterday, they revealed initial results from a pioneering human study using UP421, an engineered islet cell therapy using Sanaโ€™s hypoimmune technology, in a type 1 diabetes patient without immunosuppression.

Key Highlights:

First-in-Human Study Shows that Sanaโ€™s Hypoimmune Technology Allows Transplanted Islet Cells to Evade Immune Rejection and Produce Insulin Without Immunosuppression.

Results Indicate that HIP-Engineered Islet Cells Evade Immune Detection, Functioning, and Persist Following Intramuscular Transplantation in the Initial Patient with Type 1 Diabetes.

Function and Persistence of Pancreatic Islets Were Detected through Steady Circulating C-Peptide Levels, a Marker of Insulin Production, and Increased C-Peptide Levels during a Mixed Meal Tolerance Test.

MRI Results Indicate Consistent Graft Survival Signals 28 Days Post-Transplantation.

Conference Call Scheduled for 1:30 pm PT with a Live Webcast.

As a result, shares of SANA witnessed over a 240% increase in pre-market trading.

AD 4nXfef5fydjo0OsQNNPQ3nNIcByy DUIIgIW7T1fCdmYaDotQbBjfcPGcUjaXzcsCs4MBObdyQIMCqIi1iS fDudc8aqQOBvv0tLDDlEhCxg 5LfUXmXH5h4YRVk2tT7lR L69rbDJg?key=KKX Zz6252ck8DpWy4i7775e

The $5.22 level acted as support in pre-market trading and is crucial to monitor.

If it remains above, targets to reach are $5.90, $6.10, $7.25, and then the pre-market high of $8.12. Further on, $9 and $10 may also come into play.

If it drops below $5.22, watch for targets down to $4.75, $4.35, $3.80, $2.85, $2.30, and then $2.


CURR โ€“ Gained over 180% in pre-market following the launch of SEAMLESS AI call center solutions.

CURRENC Group Inc. (CURR) is at the forefront of fintech and digital remittance, catering to millions of unbanked and underbanked individuals throughout Southeast Asia and more.

In pre-market trading today, the company announced the rollout of its SEAMLESS AI Call Centre Solutions, an array of AI-driven tools designed to lower costs, enhance efficiency, and improve customer satisfaction across various sectors.

SEAMLESS AI Call Centre Solutions comprises three distinct software products, all supported by extensive data analysis capabilities that allow financial institutions to provide unmatched service experiences around the clock.

โ€œText AIโ€ enables instant Q&A and personalized follow-ups in a conversational chat format.

โ€œVoice AIโ€ offers hands-free interaction with an AI agent, guiding users seamlessly from simple queries to complex transactions or Know Your Customer procedures.

Finally, โ€œAvatar AIโ€ brings a human element to resolving queries and managing tasks through 2D or 3D avatars, simulating real-life interactions. These solutions are offered in more than 10 languages and can be easily integrated into mobile applications, providing a smooth communication channel to users globally.

As a result, shares of CURR surged over 150% in pre-market trading.

AD 4nXdjmG7DQjIw1CNIHw3xkuGV20nuAFd2s26jEfTF94NjhtuHoGsrvC4ZigBsX4I7ZAk47IzuAZk68y7Z7QLu EDPPqAkCPUZjgYSsVLYf3oRUXw4lq1e4MLhdOcoDuBnV2wpiBS58Q?key=KKX Zz6252ck8DpWy4i7775e

The immediate target for bulls is pre-market resistance at $4.10, followed by $4.30 and the pre-market high at $4.56. Then the targets move to $5 and $5.74.

If it falls below $4.10, possible downside targets are $3.55, $3.20, $2.83, $2.68, $2.20, $1.85, $1.50, and a gap fill at $1.39.


Seeking unbiased, fact-based news? Join 1440 today.

1aae14d18ebe7ada398a3688410a72a3

Elevate your news experience with 1440! Subscribe to a daily newsletter trusted by millions for its concise, 5-minute overview of global news. We sift through over 100 sources to deliver factual news on politics, business, and cultureโ€”without bias and completely free.

Join 1440 today.


ABSI โ€“ Increased over 50% in pre-market after announcing its strategic partnership and investment with AMD to advance AI drug discovery.

Absci Corporation (ABSI) operates as a leader in data-driven generative artificial intelligence (AI) for drug creation in the United States.

In pre-market trading today, they reported a strategic partnership with AMD to utilize AMD Instinctโ„ข accelerators and ROCmโ„ข software for essential AI drug discovery operations, focusing on Absciโ€™s advanced de novo antibody design models.

Additionally, AMD will make a $20 million investment in Absci, categorized as a private investment in public equity (PIPE), highlighting the growing demand for innovative AI tools in drug research.

Consequently, shares of ABSI rose over 50% in pre-market trading following the news.

The $4.42 area previously served as resistance in the pre-market and is now viewed as a potential support level.

If it maintains above, upside targets could include $5 and the pre-market high at $5.15, followed by $5.40, $5.80, and $6.20.

However, if it falls below $4.42, downside targets to watch are $4, $3.70, $3.50, and a gap fill at $3.07.


MARKET NEWS ๐Ÿ“ฐ

AD 4nXctvzd1nwAYQ HEMQ8XmzFMTOAcYr NQNqL J1ZnE5nBdfbxJxZtU wn ZsJulzU6ZEl 1YK6Ih kQNyU4O zndM4hs 5nCs9xgkHc5YzdJdHx XfCvqaZn 8cEorjbcV2vdAeh3w?key=KKX Zz6252ck8DpWy4i7775e

DISCLAIMER
: For a complete understanding of any service offered by Ragingbull.com, LLC (โ€œRagingBullโ€), please review our full disclaimer available at
https://ragingbull.com/disclaimer

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE.
All services provided by RagingBull are intended for educational and informational purposes only, and should NOT be interpreted as a securities offer or solicitation, nor should it be considered personalized investment advice. We strongly advise consulting a licensed or registered professional before making any investment decisions.

RESULTS PRESENTED NOT TYPICAL OR VERIFIED.
Information relating to past trading performance from RagingBullโ€™s owners or employees, along with testimonials, may be presented. However, subscriber results are NOT tracked or verified, and past performance is not indicative of future results. The outcomes outlined in this communication may not be typical. Individual results will vary based on experience, skill, risk management, market conditions, and capital invested. Investing in securities is speculative and involves significant risk; there is potential for loss, including substantial losses beyond your initial investment.

RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER.
RagingBull, along with its owners and employees, are not registered as securities broker-dealers, brokers, investment advisors, or IA representatives with the U.S. Securities and Exchange Commission, any state securities authority, or any self-regulating organization. Payment for services rendered may be commission-based according to sales to subscribers.

RagingBull.com, LLC is entitled to recovery of legal fees, costs, and disbursements.
Should any legal actions arise from transactions with RagingBull.com, LLC or its affiliates, RagingBull.com, LLC is entitled to collect legal fees, costs, and other reliefs.

*Sponsored Content:
If you purchase anything through a link in this email other than RagingBull services, itโ€™s important to assume we share an affiliate relationship with the company involved and that compensation may be received. We encourage performing independent research before any purchase decisions. While we endorse these affiliate companies, we advise against unnecessary spending unless youโ€™re confident in their potential to benefit your objectives.

WE MAY HOLD SECURITIES DISCUSSED.
RagingBull has not received payment from the entity behind any security discussed in our services, possibly aside from advertisers linked in this email. However, Ragingbull.com, LLC, its owners, and employees may have positions, either long or short, in securities mentioned herein.

[adrotate group="2"]

Share This Post

Facebook
X
LinkedIn
WhatsApp
Pinterest
Reddit
Telegram
Email
Advertisement

Currency

Source: USD @ Sat, 10 May.